ClinicalTrials.gg
RecruitingNCT06573476Updated May 27, 2026

Addressing Racial Disparities in Opioid Overdose Using Peer Recovery Coach Training and mHealth Platform

An interventional study of PRC supported text + AI driven CSDH-enhanced text and AI driven CSDH-enhanced text only in Opioid Use Disorder, sponsored by Friends Research Institute, Inc.. Recruiting at 1 site in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-05-27.

Sponsored by Friends Research Institute, Inc. · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Opioid-Related Disorders by Friends Research Institute, Inc. — 4 open to participants now, 7 under way, 3 of them phase 3. Opioid-Related Disorders · Friends Research Institute, Inc..

Planned enrollment
13th of 20
180 · median 235
Started
2025
with 4 others
No phase
11 of 20
3 open now
Registered
17th of 20
by date

Among the 20 studies in Opioid-Related Disorders by Friends Research Institute, Inc., this one is the 13th largest by planned enrollment, is one of 5 that started in 2025, is one of 11 with no phase, and was the 17th registered.

Opioid-Related Disorders

1,476 studies on the registry are indexed under Opioid-Related Disorders; 293 are open to participants now.

Browse Opioid-Related Disorders studies →

Open to participants now

4 of the 20 studies in Opioid-Related Disorders by Friends Research Institute, Inc. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 213 Opioid-Related Disorders studies recruiting now, 123 (58%) set no upper age limit and 76 (36%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Opioid-Related Disorders by Friends Research Institute, Inc., or all of them as a file.
02

Study summary

The study aims to adapt an existing Cultural Structural Humility (CSH) training into a video format for peer recovery coaches (PRCs) and refine an AI-driven texting tool to reinforce the training. After refining these tools using user-centered design, a pilot test will be conducted to assess their impact on the uptake of opioid treatment and social services. The study will also evaluate the feasibility and effectiveness of the intervention to inform future large-scale trials.

Read the detailed description

The purpose of this study is to adapt an evidence-supported, currently staff-led Cultural Structural Humility (CSH) training to an interactive video format (7 brief video modules) for PRCs (Aim 1) while concurrently, refining a validated AI-driven texting tool that will newly reinforce core CSH training principles (Aim 2) that focus upon cultural and structural determinants of health (CSDH). After completing iterative refinement per user-centered design strategies based on the Technology Acceptance Model (TAM) for Aim 1 and 2, the investigators will pilot test CSH-trained PRCs delivering telephone based care/services coordination combined with refined AI-driven texting to enhance uptake of MOUD services, and social services (Aim 3). Aim 3 is sized for feasibility testing, final 'de-bugging' of the platform, and informing study conceptualization for a future large-scale efficacy trial. In this R34, the intervention effects will be assessed on the primary clinical outcome (i.e., receipt of buprenorphine), secondary outcome (i.e., uptake of social services), and implementation of the proposed multimodal intervention platform per the RE-AIM framework.

03

Conditions studied

  • Opioid Use Disorder

Keywords

  • Opioid Use Disorder
  • Peer Recovery Coach
  • Cultural Structural Humility
  • mHealth
  • People With Opioid Use Disorder
  • OUD
  • PWOUD
  • mHealth Intervention
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥18 years of age
  • fluent in English
  • self-reported non-prescription opioid use \<30 days prior to consent
  • provision of
  • planned stay in NYC ≥3 months
  • Black and/or Latinx race/ethnicity
  • positive urine toxicology for opioids per EMR records or study staff administered random saliva drug testing
  • diagnosis of OUD per the -5 (DSM-5)
  • self-reported interest in initiating buprenorphine in primary care, or elsewhere.

Exclusion criteria

Exclusion Criteria:

  • inability to comprehend text content written at a 3rd grade reading level
  • physical or visual disability preventing mobile phone use
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    Intervention Arm-1: PRC supported text+ AI driven CSDH-enhanced text

    Individuals randomized to Arm-1 will receive PRC-supported text check-ins and AI-driven CSDH-enhanced text messaging.

    Behavioral: PRC supported text + AI driven CSDH-enhanced text

  • Experimental
    Intervention Arm-2: AI driven CSDH-enhanced text only

    Individuals randomized to Arm-2 will receive the AI-driven CSDH-enhanced text messaging only

    Behavioral: AI driven CSDH-enhanced text only

  • Placebo comparator
    Control Arm 3- Treatment as Usual

    Individuals randomized to the control arm will receive treatment as usual.

    Behavioral: Treatment as Usual (TAU)

Interventions

  • BehavioralPRC supported text + AI driven CSDH-enhanced text

    In interventional Arm-1, PRC-supported text check-ins to participants (3x/week) will be provided by PRC study staff in addition to automated AI-driven texts. The PRC will personalize text "check-ins" to participants based on: (a) baseline CSDH needs (e.g., food insecurity, legal aid); (b) initial intake visit in primary care or challenges with service entry; and (c) content outlined in the CSH training addressing emerging participant challenges.

  • BehavioralAI driven CSDH-enhanced text only

    In interventional Arm-2, participants will receive the AI-driven CSDH-enhanced text messaging only. Participants in this arm will not receive text support from the PRC.

  • BehavioralTreatment as Usual (TAU)

    In Arm-3, the control group, individuals randomized to the control arm will receive treatment as usual (i.e., verbal instructions and NYC Dept of Health pamphlets detailing access to OUD and social services). No services will be provided except for social/clinical service referrals given at the end of each REDCap visit.

06

What researchers measure

Primary outcomes

  1. Estimated Rate of PRC-PWUO Contact

    The number of contacts between Peer Recovery Coaches (PRC) and People Who Use Opioids (PWUO), measured through communication logs.

    Time frame: 3 months

  2. Rate of AI-Driven Texting Use Among PWUO

    The frequency of AI-driven text interactions initiated by PWUO, captured through software logs.

    Time frame: 3 months

  3. Change in Felt and/or Anticipated Stigma

    The change in felt and/or anticipated stigma pre- and post-intervention, measured by a validated stigma assessment questionnaire.

    Time frame: 3 months

  4. Amount of time to Initial Receipt of Buprenorphine (Self-Reported)

    The time (in days) to the initial receipt of buprenorphine, as self-reported by participants.

    Time frame: 3 months

  5. The Amount of Self-Reported Social Services Use

    The self-reported utilization of social services at baseline, 1 month, and 3 months, addressing social determinants of health (SDH) to assess intervention effect sizes.

    Time frame: 3 months

  6. Cost (Amount of Money) of Implementing and Sustaining the Multimodal Intervention

    The associated cost of implementing and sustaining the multimodal intervention, including cost-per quality-adjusted life year (QALY) and cost-per opioid use disorder (OUD) treatment days.

    Time frame: 3 months

Secondary outcomes

  1. The Amount of Participants That Retain in Treatment

    The number of participants continuously retained in buprenorphine treatment over a 12-week period, assessed at the 12-week mark.

    Time frame: 3 months

07

Study locations

1 of 1 sites recruiting
  • START Treatment and Recovery
    New York, New York 11238, United States
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Mar 2027, 20 months after the start.

Of 465 non-industry interventional studies with no phase under Opioid-Related Disorders, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 47. This study's planned 20 months is below that.

Counting every sponsor, half of 496 studies reached it within 29 months; a quarter within 13 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2024
First posted
Aug 27, 2024
StartActual
Jun 25, 2025
Primary completionEst.
Mar 1, 2027
CompletionEst.
Mar 15, 2027
Last update
May 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06573476
Lead sponsor
Friends Research Institute, Inc.
Collaborators
Nathan Kline Institute for Psychiatric Research, NYU Langone Health
Responsible party
Sponsor
First posted
Aug 27, 2024
Start date
Jun 25, 2025
Primary completion
Mar 1, 2027 (estimated)
Completion
Mar 15, 2027 (estimated)
Last update
May 27, 2026

Study contacts

Ana Ventuneac, PHd
Contact
aventuneac@startny.org
718-260-2931
Ana Ventuneac
study director · START Treatment and Recovery

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion